Get started
Author

Dana Paskalis

Observed name: D. Paskalis
ORCID: 0000-0003-3840-0504
Observed ORCID: 0000-0003-3840-0504
OpenAlex ID: A5030596983
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy
2020 · Anthony R. Mato, Nilanjan Ghosh, et al. · Blood · 49
Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation
2018 · Anthony R. Mato, Jakub Svoboda, et al. · Blood · 21
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach
2022 · Lindsey E. Roeker, Tatyana A. Feldman, et al. · Clinical Cancer Research · 14
PDF
Phase I/ii Study of Umbralisib (tgr‐1202) in Combination With Ublituximab (tg‐1101) and Pembrolizumab in Patients With Rel/ref Cll and Richter's Transformation
2019 · A.R. Mato, J. Svoboda, et al. · Hematological Oncology · 10
A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3Kδ inhibitor therapy.
2018 · Anthony R. Mato, Stephen J. Schuster, et al. · Journal of Clinical Oncology · 6
A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib in Patients With Chronic Lymphocytic Leukemia (cll) Who Are Intolerant to Prior Btk or Pi3k Delta Inhibitor Therapy
2019 · A.R. Mato, S.J. Schuster, et al. · Hematological Oncology · 5
Supplementary Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach
2023 · Lindsey E. Roeker, Tatyana A. Feldman, et al.
Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach
2023 · Lindsey E. Roeker, Tatyana A. Feldman, et al.
Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach
2023 · Lindsey E. Roeker, Tatyana A. Feldman, et al.
KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy.
2017 · Colleen Dorsey, Dana Paskalis, et al. · Journal of Clinical Oncology
Works count: 10
Citation count: 105
H-index: 5
I10-index: 4
Year
Topic
Type